Brind.
  1. Eli Lilly raised Zepbound prices in the U.K. and plans to follow price hikes across Europe, while Novo Nordisk received a drug price reduction letter amid Trump administration pressure.
  2. The FDA has ruled on copycat drugs produced in China, while Novo Nordisk navigates price reduction demands from Trump and leadership changes.
  3. Trump administration announced FDA coverage changes regarding Chinese suppliers who are not registered.
  4. The Trump administration is leading to FDA job cuts, while Elon Musk spearheaded the Department of Government Efficiency, and China has surpassed the US in clinical trial volume.

Trump administration proposes new approaches to stretch FDA resources, involving Michael Rogers.

1 report, 1 independent Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Trump administration proposes new approaches to stretch FDA resources, involving Michael Rogers.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped